<p>Disc Medicine, Inc.（纳斯达克代码：IRON - 免费报告）- HC Wainwright 的股票分析师在 5 月 6 日星期三向客户和投资者发布的研究报告中上调了 Disc Medicine 的 2030 财年每股收益（EPS）预期。HC Wainwright 分析师 D. Tsao 现在预计该公司将实现每股收益 7.40 美元，高于之前预测的 7.12 美元。Disc Medicine 当前全年的共识预期收益为每股（6.68 美元）。</p>
<p>获取 <strong>Disc Medicine</strong> 警报：</p>
<p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）在 5 月 5 日星期二发布了季度财报。该公司报告季度每股收益（EPS）为（1.65 美元），低于共识预期的（1.62 美元）3 美分。</p>
<p>其他研究分析师最近也发布了关于该股票的报告。富国银行将 Disc Medicine 的目标股价从 78.00 美元上调至 79.00 美元，并在 3 月 2 日的报告中给予该股票 “超配” 评级。摩根士丹利在 2 月 17 日的报告中将 Disc Medicine 的目标股价设定为 75.00 美元。Cantor Fitzgerald 在 2 月 17 日的报告中将 Disc Medicine 的目标股价从 153.00 美元下调至 125.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 4 月 20 日的报告中重新发布了 Disc Medicine 的 “卖出（d-）” 评级。最后，Raymond James Financial 在 1 月 15 日的研究报告中重申了 Disc Medicine 的 “市场表现” 评级。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 104.80 美元。</p>
<p><strong>阅读我们最新的 Disc Medicine 股票分析</strong></p>
<h2>Disc Medicine 股价上涨 1.6%</h2>
<p>纳斯达克 IRON 在星期四开盘价为 68.65 美元。该股票的市值为 26.2 亿美元，市盈率为-10.37，贝塔值为 0.93。Disc Medicine 的 52 周低点为 40.00 美元，52 周高点为 99.50 美元。该公司的 50 日移动平均价格为 65.01 美元，200 日移动平均价格为 76.09 美元。该公司的速动比率为 21.94，流动比率为 21.94，债务与股本比率为 0.04。</p>
<h2>Disc Medicine 的机构交易</h2>
<p>一些对冲基金最近买入和卖出了该公司的股票。RA Capital Management L.P.在第四季度将其在 Disc Medicine 的持股增加了 25.3%。RA Capital Management L.P.现在拥有 1,976,132 股该公司的股票，价值 156,925,000 美元，此前在上个季度额外购买了 399,026 股。先锋集团在第四季度将其在 Disc Medicine 的持股增加了 22.1%。先锋集团现在拥有 1,767,680 股该公司的股票，价值 140,371,000 美元，此前在该期间额外购买了 319,621 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Disc Medicine 的持股增加了 28.0%。Price T Rowe Associates Inc. MD 现在拥有 1,698,005 股该公司的股票，价值 134,839,000 美元，此前在该期间额外购买了 371,576 股。摩根大通在第四季度将其在 Disc Medicine 的持股增加了 110.0%。摩根大通现在拥有 1,581,127 股该公司的股票，价值 125,557,000 美元，此前在该期间额外购买了 828,248 股。最后，威灵顿管理集团在第四季度将其在 Disc Medicine 的持股增加了 7.7%。威灵顿管理集团现在拥有 1,518,274 股该公司的股票，价值 120,566,000 美元，此前在该期间额外购买了 108,197 股。机构投资者和对冲基金持有该公司 83.70% 的股票。</p>
<h2>内部活动</h2>
<p>在相关消息中，首席财务官 Jean M. Franchi 在 4 月 14 日星期二出售了 6,257 股该公司的股票。股票以平均价格 69.24 美元出售，总交易额为 433,234.68 美元。出售后，首席财务官在公司中持有 64,333 股，价值约为 4,454,416.92 美元。此交易代表其持股减少了 8.86%。该出售在与证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，内部人士 Pamela Stephenson 在 2 月 17 日星期二出售了 5,531 股该公司的股票。股票以平均价格 62.86 美元出售，总交易额为 347,678.66 美元。出售后，内部人士在公司中持有 80,998 股，价值约为 5,091,534.28 美元。此交易代表其持股减少了 6.39%。有关此出售的更多详细信息可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了 59,410 股公司股票，价值 3,840,013 美元。内部人士持有该公司 3.64% 的股票。</p>
<h2>Disc Medicine 公司简介</h2>
<p>（获取免费报告）</p>
<p>Disc Medicine, Inc. 纳斯达克：IRON 是一家临床阶段的生物技术公司，专注于发现和开发精准医学，以恢复严重遗传和获得性疾病中的正常细胞功能。该公司采用以化学为驱动的方法，识别选择性调节 RNA 结合蛋白或剪接调控通路的小分子。通过利用专有的筛选和药物化学平台，Disc Medicine 旨在解决具有高度未满足医疗需求和有限治疗选择的疾病。</p>
<p>该公司的产品线以针对神经肌肉和血液疾病的主要项目为基础。</p>
<h2>另见</h2>
<ul>
<li>我们更喜欢的五只股票超过 Disc Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
<p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Disc Medicine 并不在名单上。</p>
<p>虽然 Disc Medicine 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IRON

<p>Disc Medicine, Inc.（纳斯达克代码：IRON）其 2030 财年每股收益（EPS）预测被 HC Wainwright 从 7.12 美元上调至 7.40 美元。该公司报告的季度每股收益为（1.65 美元），未能达到预期。分析师的目标价格各不相同，富国银行将其目标价上调至 79.00 美元。该股票目前的共识评级为 “适度买入”，交易价格为 68.65 美元，市值为 26.2 亿美元。机构投资者持有该股票的 83.70%，并且最近有内部人士出售股票的报告</p>

<p>Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at HC Wainwright upped their FY2030 EPS estimates for Disc Medicine in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $7.40 per share for the year, up from their previous forecast of $7.12. The consensus estimate for Disc Medicine's current full-year earnings is ($6.68) per share.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（纳斯达克代码：IRON - 免费报告）- HC Wainwright 的股票分析师在 5 月 6 日星期三向客户和投资者发布的研究报告中上调了 Disc Medicine 的 2030 财年每股收益（EPS）预期。HC Wainwright 分析师 D. Tsao 现在预计该公司将实现每股收益 7.40 美元，高于之前预测的 7.12 美元。Disc Medicine 当前全年的共识预期收益为每股（6.68 美元）。</p>
</div><p>Get <strong>Disc Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Disc Medicine</strong> 警报：</p>
</div><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03).</p>
<div class="lb-trans"><p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）在 5 月 5 日星期二发布了季度财报。该公司报告季度每股收益（EPS）为（1.65 美元），低于共识预期的（1.62 美元）3 美分。</p>
</div><p>Other research analysts have also recently issued reports about the stock. Wells Fargo &amp; Company increased their price target on shares of Disc Medicine from $78.00 to $79.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, March 2nd. Morgan Stanley set a $75.00 price target on shares of Disc Medicine in a report on Tuesday, February 17th. Cantor Fitzgerald cut their price target on shares of Disc Medicine from $153.00 to $125.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, February 17th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Raymond James Financial restated a &#34;market perform&#34; rating on shares of Disc Medicine in a research report on Thursday, January 15th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $104.80.</p>
<div class="lb-trans"><p>其他研究分析师最近也发布了关于该股票的报告。富国银行将 Disc Medicine 的目标股价从 78.00 美元上调至 79.00 美元，并在 3 月 2 日的报告中给予该股票 “超配” 评级。摩根士丹利在 2 月 17 日的报告中将 Disc Medicine 的目标股价设定为 75.00 美元。Cantor Fitzgerald 在 2 月 17 日的报告中将 Disc Medicine 的目标股价从 153.00 美元下调至 125.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 4 月 20 日的报告中重新发布了 Disc Medicine 的 “卖出（d-）” 评级。最后，Raymond James Financial 在 1 月 15 日的研究报告中重申了 Disc Medicine 的 “市场表现” 评级。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 104.80 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Disc Medicine</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 Disc Medicine 股票分析</strong></p>
</div><h2>Disc Medicine Trading Up 1.6%</h2>
<div class="lb-trans"><h2>Disc Medicine 股价上涨 1.6%</h2>
</div><p>NASDAQ IRON opened at $68.65 on Thursday. The stock has a market capitalization of $2.62 billion, a P/E ratio of -10.37 and a beta of 0.93. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The firm has a 50-day moving average price of $65.01 and a 200 day moving average price of $76.09. The company has a quick ratio of 21.94, a current ratio of 21.94 and a debt-to-equity ratio of 0.04.</p>
<div class="lb-trans"><p>纳斯达克 IRON 在星期四开盘价为 68.65 美元。该股票的市值为 26.2 亿美元，市盈率为-10.37，贝塔值为 0.93。Disc Medicine 的 52 周低点为 40.00 美元，52 周高点为 99.50 美元。该公司的 50 日移动平均价格为 65.01 美元，200 日移动平均价格为 76.09 美元。该公司的速动比率为 21.94，流动比率为 21.94，债务与股本比率为 0.04。</p>
</div><h2>Institutional Trading of Disc Medicine</h2>
<div class="lb-trans"><h2>Disc Medicine 的机构交易</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. boosted its position in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after acquiring an additional 399,026 shares during the last quarter. Vanguard Group Inc. raised its stake in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. JPMorgan Chase &amp; Co. raised its stake in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase &amp; Co. now owns 1,581,127 shares of the company's stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. Finally, Wellington Management Group LLP raised its stake in Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock worth $120,566,000 after purchasing an additional 108,197 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。RA Capital Management L.P.在第四季度将其在 Disc Medicine 的持股增加了 25.3%。RA Capital Management L.P.现在拥有 1,976,132 股该公司的股票，价值 156,925,000 美元，此前在上个季度额外购买了 399,026 股。先锋集团在第四季度将其在 Disc Medicine 的持股增加了 22.1%。先锋集团现在拥有 1,767,680 股该公司的股票，价值 140,371,000 美元，此前在该期间额外购买了 319,621 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Disc Medicine 的持股增加了 28.0%。Price T Rowe Associates Inc. MD 现在拥有 1,698,005 股该公司的股票，价值 134,839,000 美元，此前在该期间额外购买了 371,576 股。摩根大通在第四季度将其在 Disc Medicine 的持股增加了 110.0%。摩根大通现在拥有 1,581,127 股该公司的股票，价值 125,557,000 美元，此前在该期间额外购买了 828,248 股。最后，威灵顿管理集团在第四季度将其在 Disc Medicine 的持股增加了 7.7%。威灵顿管理集团现在拥有 1,518,274 股该公司的股票，价值 120,566,000 美元，此前在该期间额外购买了 108,197 股。机构投资者和对冲基金持有该公司 83.70% 的股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, CFO Jean M. Franchi sold 6,257 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the sale, the chief financial officer owned 64,333 shares in the company, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the sale, the insider owned 80,998 shares in the company, valued at approximately $5,091,534.28. This trade represents a 6.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,410 shares of company stock valued at $3,840,013 in the last 90 days. Insiders own 3.64% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Jean M. Franchi 在 4 月 14 日星期二出售了 6,257 股该公司的股票。股票以平均价格 69.24 美元出售，总交易额为 433,234.68 美元。出售后，首席财务官在公司中持有 64,333 股，价值约为 4,454,416.92 美元。此交易代表其持股减少了 8.86%。该出售在与证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，内部人士 Pamela Stephenson 在 2 月 17 日星期二出售了 5,531 股该公司的股票。股票以平均价格 62.86 美元出售，总交易额为 347,678.66 美元。出售后，内部人士在公司中持有 80,998 股，价值约为 5,091,534.28 美元。此交易代表其持股减少了 6.39%。有关此出售的更多详细信息可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了 59,410 股公司股票，价值 3,840,013 美元。内部人士持有该公司 3.64% 的股票。</p>
</div><h2>Disc Medicine Company Profile</h2>
<div class="lb-trans"><h2>Disc Medicine 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.</p>
<div class="lb-trans"><p>Disc Medicine, Inc. 纳斯达克：IRON 是一家临床阶段的生物技术公司，专注于发现和开发精准医学，以恢复严重遗传和获得性疾病中的正常细胞功能。该公司采用以化学为驱动的方法，识别选择性调节 RNA 结合蛋白或剪接调控通路的小分子。通过利用专有的筛选和药物化学平台，Disc Medicine 旨在解决具有高度未满足医疗需求和有限治疗选择的疾病。</p>
</div><p>The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.</p>
<div class="lb-trans"><p>该公司的产品线以针对神经肌肉和血液疾病的主要项目为基础。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Disc Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Disc Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=IRON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
</div><p>Before you consider Disc Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Disc Medicine 并不在名单上。</p>
</div><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Disc Medicine 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 上调了 Disc Medicine 2030 财年的每股收益预测